TY - JOUR AU - Srivastava, Sushmita; Haider, Md. Faheem; Ahmad, Afroz; Ahmad, Usama; Arif, Muhammad; Ali, Asad TI - Exploring Nanoemulsions for Prostate Cancer Therapy SN - 2194-9379 SN - 2194-9387 PY - 2021 JO - Drug Res (Stuttg) JF - Drug Research LA - EN VL - 71 IS - 08 SP - 417 EP - 428 DA - 2021/06/22 KW - protooncogenes KW - carcinoma KW - prostatectomy KW - nanomedicine KW - nanoemulsification KW - targeting KW - proliferation KW - cytotoxicity KW - apoptosis AB - Prostate carcinoma is typical cancer. It is the second most common cancer globally. The estimated new cases in 2020 was 191 930 and estimated deaths was 33 330. Age, family history, & genetic factors are major factors that drive prostate cancer. Although, for treating metastatic disease, the major therapies available are radiation,bisphosphonate, and palliative chemotherapy. But the major drawback is therapy is disease-driven and later becomes metastatic and requires treatment. The ability to revolutionize cancer treatment by major targeting vehicles via the exploration of nanoemulsion suggests a potential for cancer treatment. The unique property of a biphasic liquid dosage form called nanoemulsion to reach leaky tumor vasculature is due to its nano-meter oil-droplet size of 20–200 nm. Recent reporting on nanoemulsions disclose their embracing and lay alternative for re-purposing herbal and synthetic drugs and their combination especially for targeting prostate cancer formulating an obtainable nanomedicine. So, this article emphasizes the use of nanoemulsions incorporating therapeutic agents for successful and targeted delivery for prostate cancer. PB - Georg Thieme Verlag KG DO - 10.1055/a-1518-6606 UR - http://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1518-6606 ER -